Where can I find UTHR's financial statements?

United Therapeutics Corporation (UTHR)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for UTHR?

United Therapeutics Corporation (UTHR) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does UTHR update its statements?

United Therapeutics Corporation files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

UTHR

United Therapeutics Corporation

NASDAQ·Biotechnology · Healthcare

$527.07$8.76−1.63%

After hours·$527.07+0.00%

Market cap$22.37B·Market closed·Jul 22 8:00 PM UTC

USD · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	$1.69B+13.6%	$1.94B+14.9%	$2.33B+20.2%	$2.88B+23.6%	$3.18B+10.6%
Cost of revenue	$122.50M+13.3%	$146.70M+19.8%	$257.50M+75.5%	$309.70M+20.3%	$384.40M+24.1%
Gross profit	$1.56B+13.7%	$1.79B+14.5%	$2.07B+15.7%	$2.57B+24.0%	$2.80B+9.0%
Research & development	$540.10M+51.0%	$322.90M−40.2%	$408.00M+26.4%	$481.00M+17.9%	$550.00M+14.3%
General & administrative	$402.60M+9.1%	$416.20M+3.4%	$395.30M−5.0%	$542.30M+37.2%	$612.50M+12.9%
Selling & marketing	$64.40M+17.3%	$70.80M+9.9%	$81.80M+15.5%	$96.30M+17.7%	$118.60M+23.2%
SG&A (combined)	$467.00M+10.2%	$487.00M+4.3%	$477.10M−2.0%	$638.60M+33.9%	$731.10M+14.5%
Other operating expenses	—	—	—	$71.10M	—
Total operating expenses	$1.01B+28.9%	$809.90M−19.6%	$885.10M+9.3%	$1.19B+34.5%	$1.28B+7.6%
Operating income	$555.90M−6.4%	$979.70M+76.2%	$1.18B+20.9%	$1.38B+16.2%	$1.52B+10.2%
Interest income	$16.70M−41.6%	$45.20M+170.7%	$162.70M+260.0%	$199.10M+22.4%	$192.00M−3.6%
Interest expense	$18.60M−20.9%	$32.40M+74.2%	$59.30M+83.0%	$42.90M−27.7%	$19.50M−54.5%
Other income / (expense), net	$38.00M−16.1%	−$29.10M−176.6%	$89.40M+407.2%	$162.00M+81.2%	$196.70M+21.4%
Income before tax	$593.90M−7.0%	$950.60M+60.1%	$1.27B+34.1%	$1.54B+20.8%	$1.71B+11.4%
Income tax expense	$118.10M−4.8%	$223.30M+89.1%	$289.50M+29.6%	$343.90M+18.8%	$379.20M+10.3%
Net income	$475.80M−7.6%	$727.30M+52.9%	$984.80M+35.4%	$1.20B+21.4%	$1.33B+11.7%

EPS (basic)	$10.60−9.0%	$15.98+50.8%	$21.04+31.7%	$26.44+25.7%	$30.13+14.0%
EPS (diluted)	$10.06−12.8%	$15.00+49.1%	$19.81+32.1%	$24.64+24.4%	$27.86+13.1%
Weighted avg shares (basic)	44,900,000	45,500,000	46,800,000	45,200,000	44,300,000
Weighted avg shares (diluted)	47,300,000	48,500,000	49,700,000	48,500,000	47,900,000

Depreciation & amortization	$49.90M+0.0%	$51.30M+2.8%	$53.20M+3.7%	$72.50M+36.3%	$85.60M+18.1%
EBITDA	$736.80M+14.0%	$1.04B+41.2%	$1.39B+33.3%	$1.65B+19.3%	$1.82B+9.9%

Frequently Asked Questions About UTHR

Where can I find UTHR's financial statements?: United Therapeutics Corporation (UTHR)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for UTHR?: United Therapeutics Corporation (UTHR) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does UTHR update its statements?: United Therapeutics Corporation files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

$1.69B+13.6%

$1.94B+14.9%

$2.33B+20.2%

$2.88B+23.6%

$3.18B+10.6%

Cost of revenue

$122.50M+13.3%

$146.70M+19.8%

$257.50M+75.5%

$309.70M+20.3%

$384.40M+24.1%

Gross profit

$1.56B+13.7%

$1.79B+14.5%

$2.07B+15.7%

$2.57B+24.0%

$2.80B+9.0%

Research & development

$540.10M+51.0%

$322.90M−40.2%

$408.00M+26.4%

$481.00M+17.9%

$550.00M+14.3%

General & administrative

$402.60M+9.1%

$416.20M+3.4%

$395.30M−5.0%

$542.30M+37.2%

$612.50M+12.9%

Selling & marketing

$64.40M+17.3%

$70.80M+9.9%

$81.80M+15.5%

$96.30M+17.7%

$118.60M+23.2%

SG&A (combined)

$467.00M+10.2%

$487.00M+4.3%

$477.10M−2.0%

$638.60M+33.9%

$731.10M+14.5%

Other operating expenses

—

$71.10M

—

Total operating expenses

$1.01B+28.9%

$809.90M−19.6%

$885.10M+9.3%

$1.19B+34.5%

$1.28B+7.6%

Operating income

$555.90M−6.4%

$979.70M+76.2%

$1.18B+20.9%

$1.38B+16.2%

$1.52B+10.2%

Interest income

$16.70M−41.6%

$45.20M+170.7%

$162.70M+260.0%

$199.10M+22.4%

$192.00M−3.6%

Interest expense

$18.60M−20.9%

$32.40M+74.2%

$59.30M+83.0%

$42.90M−27.7%

$19.50M−54.5%

Other income / (expense), net

$38.00M−16.1%

−$29.10M−176.6%

$89.40M+407.2%

$162.00M+81.2%

$196.70M+21.4%

Income before tax

$593.90M−7.0%

$950.60M+60.1%

$1.27B+34.1%

$1.54B+20.8%

$1.71B+11.4%

Income tax expense

$118.10M−4.8%

$223.30M+89.1%

$289.50M+29.6%

$343.90M+18.8%

$379.20M+10.3%

Net income

$475.80M−7.6%

$727.30M+52.9%

$984.80M+35.4%

$1.20B+21.4%

$1.33B+11.7%

EPS (basic)

$10.60−9.0%

$15.98+50.8%

$21.04+31.7%

$26.44+25.7%

$30.13+14.0%

EPS (diluted)

$10.06−12.8%

$15.00+49.1%

$19.81+32.1%

$24.64+24.4%

$27.86+13.1%

Weighted avg shares (basic)

44,900,000

45,500,000

46,800,000

45,200,000

44,300,000

Weighted avg shares (diluted)

47,300,000

48,500,000

49,700,000

48,500,000

47,900,000

Depreciation & amortization

$49.90M+0.0%

$51.30M+2.8%

$53.20M+3.7%

$72.50M+36.3%

$85.60M+18.1%

EBITDA

$736.80M+14.0%

$1.04B+41.2%

$1.39B+33.3%

$1.65B+19.3%

$1.82B+9.9%